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Rosacea is one of the most common dermatoses of
adults. Recent studies have improved our under-
standing of the pathophysiology of rosacea. Current
concepts suggest that known clinical trigger factors of
rosacea such as UV radiation, heat, cold, stress, spicy
food, and microbes modulate Toll-like receptor
signaling, induce reactive oxygen species, as well as
enhance antimicrobial peptide and neuropeptide
production. Downstream of these events cytokines
and chemokines orchestrate an inflammatory re-
sponse that leads to the recruitment and activation
of distinct leukocyte subsets and induces the char-
acteristic histopathological features of rosacea. Here
we summarize the current knowledge of the cytokine
and chemokine network in rosacea and propose
pathways that may be of therapeutic interest.
Journal of Investigative Dermatology Symposium Proceedings (2011) 15,
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INTRODUCTION
Rosacea is a common, often underdiagnosed, chronic inflam-
matory syndrome of the adult that usually develops between
the ages of 30 and 50 years (Wilkin et al., 2002; Powell, 2005).
Up to one-third of individuals of northern European origin
report a family history of rosacea (Rebora, 1993). Rosacea
mainly affects the areas of the skin that bear a high density of
seborrhoic glands, such as cheeks, nose, chin, and forehead
(Korting and Schollmann, 2009a). The disease is characterized
by a variety of primary and secondary features. Primary
features are flushing (transient erythema), persistent erythema,
teleangiectasia, as well as papules and pustules. Secondary
features are burning or stinging, plaques, dry appearance,
edema, or phyma (Wilkin et al., 2002). An ocular involvement
can be found in more than 50% of rosacea patients, and may
present as dryness, irritation, blepharitis, conjunctivitis, or
keratitis. It must be warranted that ocular rosacea can
compromise eyesight (Powell, 2005; Elewski et al., 2011).
Patterns or groupings of primary and secondary features
are used to specify rosacea into four subtypes (Wilkin et al.,
2002). Subtype 1, the erythematoteleangiectatic rosacea, is
defined by the presence of flushing and central facial
erythema. Additional possible features are edema, stinging,
and burning sensations, as well as roughness or scaling.
Subtype 2, papulopustular rosacea, is defined by persistent
erythema and transient papules or pustules. Subtype 3,
phymatous rosacea, presents with thickening skin, irregular
surface nodularities, and enlargement. Areas affected by
phymatous rosacea are chin, forehead, cheeks, ears, and
nose, with nose or rhinophyma being the most common
phenotype by far. Ocular rosacea, finally, is defined as
subtype 4. Granulomatous rosacea does not present with the
morphological patterns or combinations seen in the subtypes
1–4, and is therefore regarded as a rosacea variant. It is
characterized by hard, yellowish–brownish or red papules
and nodules that may lead to scarring.
Rosacea-like conditions include rosacea fulminans (pyo-
derma faciale), steroid-induced acneiform eruptions, and the
perioral dermatitis (Wilkin et al., 2002). Finally, in recent
years, the development of targeted cancer drugs directed
against the EGFR has led to the recognition of novel, rosacea-
like cutaneous adverse effects (Lacouture, 2006).
Rosacea histopathology is characterized by solar elastosis,
edema, perivascular lymphocytic infiltrates, abundant mast
cells, and dilated, partly irregular vascular channels (Aroni
et al., 2008; Fimmel et al., 2008). Vascular dilatations are
found at the upper and mid-dermal blood vessels (Gomaa
et al., 2007). The pustular stage of rosacea shows a dense
follicular infiltrate composed of neutrophils, as well as
abundant macrophages and dermal dendritic cells in the
perifollicular region. Interestingly, rosacea lesions with an
association of the saprophyte Demodex folliculorum
display dermal infiltrates with a predominance of CD4þ
T-helper (TH) cells over CD8þ T cells, supporting the
hypothesis that cell-mediated immune responses have an
important role in the pathogenesis of the disease (Rufli
and Buchner, 1984). Moreover, an increased number of
dermal mast cells correlated with the duration of the
disease (Aroni et al., 2008). Immunofluorescence analyses
of rosacea reveal anticollagen antibodies along with eluted
antinuclear antibodies directed against scattered dermal,
endothelial, and eccrine duct cells (Nunzi et al., 1980).
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Finally, histopathological analyses in granulomatous rosacea
show mixed lymphohistiocytic infiltrates in association with
scattered epithelioid granulomas or epithelioid granulomas
(Helm et al., 1991).
Despite its prevalence, the underlying molecular and
cellular mechanisms of rosacea have remained largely
elusive. Nevertheless, clinical and histopathological findings
suggest that the features of all subtypes or variants are the
result of inflammatory processes. Accordingly, recent studies
propose that rosacea is caused by a consistently aberrant
innate immune response that finally results in the character-
istic inflammatory and vascular phenotype (Yamasaki and
Gallo, 2009). Herein, environmental stressors, such as UV
radiation, heat, cold, stress, glucocorticosteroids, hormones,
spicy food, or microbes, generate, modulate, and/or induce
reactive oxygen species (ROS), matrix metalloproteinases
(MMPs), Toll-like receptor (TLR) signaling, as well as
antimicrobial or neuropeptides. Eventually, these events
modulate the expression of crucial mediators of the immune
system such as cytokines and chemokines.
CYTOKINES
Cytokines comprise a family of structurally diverse proteins
that are best known for their important role in the immune
system. They often have pleiotropic functions and show cell
type-specific activities. Ligand-dependent cytokine receptor
signaling regulates cell activation, proliferation, differentia-
tion, survival, and migration of leukocytes and many other
cell types including keratinocytes, fibroblasts, endothelial
cells, and neuronal cells. Leukocytes are a rich source of
cytokine expression. However, structural cells may also
produce and/or store significant amounts of cytokines. An
example is the production of IL-1 family members by human
keratinocytes (Marionnet et al., 1997). Within the broad
spectrum of cytokines, subfamilies can be identified based on
receptor binding or structural aspects.
The IL-1 subfamily (IL-1a, IL-1b, IL-1 receptor antagonist
(RA), IL-18, IL-1F7, IL-1F10, IL-33, IL-36a, IL-36b, IL-36g,
and IL-36RA) is characterized by a conserved amino-acid
sequence, as well as a similar gene and three-dimensional
structure. IL-1 family members have a critical role in innate
immune responses and host defense. Notably, IL-1 receptors
share a common Toll/interleukin1 receptor-like domian motif
with TLRs and are expressed on a large variety of cell types
(Dinarello, 2009).
On the basis of receptor usage, the common b-chain
receptor-binding cytokines (GM-CSF, IL-3, and IL-5) are
separated from the common g-chain receptor subfamily (IL-2,
IL-4, IL-7, IL-9, IL-15, and IL-21). Members of both families
represent major growth and differentiation factors for
hematopoietic cells (Bagley et al., 1997).
On the other hand, the IL-6 subfamily (IL-6, IL-11,
leukemia inhibitory factor, oncostatin M, cardiotrophin-1,
ciliary neurotrophic factor, cardiotrophin-like cytokine, and
IL-31) is characterized by a helical cytokine structure and a
shared receptor subunit. Members stimulate hematopoiesis,
leukocyte differentiation, and link the immune system to the
nervous system (Hibi et al., 1996; Dillon et al., 2004).
The IL-10 cytokine subfamily includes, based on sequence
homology, IL-10, IL-19, IL-20, IL-22, IL-24, and IL-26, and is
separated from the IFN subfamily (Pestka et al., 2004). The IFN
subfamily is further divided into type I IFNs, including
IFN-a, -b, -o, -k, and Limitin, as well as the type II IFN,
IFN-g. IFNs are best known for their crucial role in host
defense and orchestrate antiviral or antitumor immune
responses, are angiostatic, and initiate autoimmune responses
(Haller and Weber, 2009; Kalliolias and Ivashkiv, 2010).
The IL-17 subfamily represents secreted proteins that share
a conserved cysteine-knot structure and comprise IL-17, IL-
17B, IL-17C, IL-17D, IL-17E (IL-25), and IL-17F. T cells are a
major source of IL-17 and use this cytokine to interact with a
broad range of cell types (Weaver et al., 2007). In particular,
IL-17 was shown to be secreted by activated CD4þ T cells
(Harrington et al., 2005). This discovery has led to the
distinction of IL-17-producing TH17 cells from TH1 or TH2
cells. Interestingly, TH17 cells have been shown to have a
crucial role in autoimmunity and neutrophilic inflammation
(Alcorn et al., 2010; Marzano et al., 2010).
Within the tumor necrosis factor (TNF) family of cytokines
(TNF-a, TNF-b, TRAIL, RANKL, TWEAK, APRIL, OX40L,
CD27L, CD30L, CD40L, LIGHT, lymphotoxin-a, and lym-
photoxin-b), most members are type II transmembrane
proteins. Their extracellular domains can be cleaved by
specific metalloproteinases to generate soluble cytokines and
exert pleiotropic functions in the immune system, organ
development, and cancer (Watts, 2005). Notably, their most
prominent member TNF-a is stored in high amounts in
dermal mast cells and is rapidly secreted upon cell activation.
Members of the TGF-b family (TGF-b1, TGF-b2, and TGF-b3)
represent structurally related proteins that form homo- or
heterodimers and signal through heteromeric receptor serine/
threonine kinases to activate Smad signaling cascades. Next
to its role in development and morphogenesis, TGF-b
signaling has been associated with fibrosis in systemic
sclerosis, idiopathic pulmonary fibrosis, keloids, and notably
phymatous tissues (Pu et al., 2000; Payne et al., 2002, 2006;
Margadant and Sonnenberg, 2010). Finally, there is a large
amount of cytokines that have not yet been clustered in
larger groups, including IL-12, IL-13, IL-16, IL-23, IL-27,
IL-32, and IL-34.
CHEMOKINES
Chemokines represent a superfamily of cytokine-like proteins
that critically regulate leukocyte trafficking (Zlotnik and
Yoshie, 2000; Zlotnik et al., 2006; Kabashima et al., 2011).
Chemokine ligands interact with 19 different seven trans-
membrane-spanning G protein-coupled receptors (CCR1-10,
CXCR1-7, XCR1, CX3CR1; Zlotnik and Yoshie, 2000). In
humans, 46 different chemokine ligands are classified into
four subfamilies based on the alignment of the first two
cysteine residues of their amino-acid sequence. Chemokines
with two consecutive cysteines are referred to as members of
the CC subfamily (CCL1-28), whereas chemokines with two
cysteines separated by one amino acid are referred to as
members of the CXC subfamily (CXCL1-17). The other two
subfamilies consist of chemokines with only one residue
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(XCL1) or chemokines with three residues in between their
cysteines (CX3CL1; Zlotnik and Yoshie, 2000). Members of
these chemokine subfamilies critically regulate the organ-
specific recruitment of distinct leukocyte subsets. With regard
to effector memory T-cell recruitment, it has been shown that
TH1 cells preferentially express CCR5 and CXCR3, TH2 cells
predominantly show CCR3, CCR4, and CCR8 on their cell
surface, whereas TH17 cells abundantly express the chemo-
kine receptor CCR6. During skin inflammation, their corre-
sponding ligands orchestrate lymphocyte recruitment to
distinct anatomical sites of the skin (Table 1: chemokine
receptor repertoire of distinct leukocyte subsets). Cutaneous
dendritic cells and macrophages serve as sentinels of the
immune system and represent a heterogeneous family of
cells. Their precursors migrate from postcapillary venules into
the skin and express many chemokine receptors, including
CCR1, CCR2, CCR5, CCR6, CXCR4, and CX3CR1, on their
cell surface. Most pronounced responses were observed for
CCR2 and its ligand CCL2 in vitro and in vivo. The formation
of pustules clinically indicates the infiltration of neutrophils
into perifollicular spaces. With regard to neutrophil recruit-
ment to the skin, ligands of CXCR2 such as CXCL1 and
CXCL8 have a dominant role and are frequently observed in
neutrophilic inflammation.
Besides their involvement in inflammation, chemokines
are involved in embryogenesis and promote tumor progres-
sion and metastasis (Muller et al., 2001; Homey et al., 2002;
Charo and Ransohoff, 2006; Pivarcsi et al., 2007; Raz and
Mahabaleshwar, 2009). During recent years, several studies
identified chemokine receptor expression on endothelial cells
and demonstrated that ligands for CCR2 (CCL2), CCR3
(CCL11), CXCR2 (CXCL1, CXCL8), CXCR4 (CXCL12), and
CX3CR1 (CX3CL1) promote angiogenesis. Conversely, IFN-
inducible and CXCR3-binding chemokines such as CXCL9,
CXCL10, and CXCL11 have been shown to inhibit angiogen-
esis and are classified as angiostatic chemokines (Gerber
et al., 2009).
Here we summarize the current knowledge of the cytokine
and chemokine network in rosacea and propose a model for
their involvement based on current pathophysiological
concepts.
THE CYTOKINE AND CHEMOKINE NETWORK IN
ROSACEA
Despite limited data on a direct involvement of cytokines and
chemokines in rosacea, these essential effectors of skin
inflammation are key mediators of the majority of symptoms,
which, according to recent studies, are proposed to be crucial
or characteristic to the pathophysiology of rosacea. There-
fore, we will discuss the role of cytokines and chemokines in
the context of these events.
INNATE IMMUNITY AND MICROBES
Current concepts propose that rosacea is caused by a
consistently aberrant innate immune response (Yamasaki
and Gallo, 2009). Herein, TLR signaling has a crucial role by
mediating the effects of well-known rosacea trigger factors.
TLRs recognize conserved products derived from microbes
(e.g., D. folliculorum) and respond to stress induced by
chemical or physical trauma (e.g., UV radiation). Subsequent
TLR activation leads to the induction of conserved anti-
pathogen signaling cascades including the secretion of
antimicrobial peptides and the production of proinflamma-
tory cytokines and chemokines (Meylan and Tschopp, 2006).
Recent studies propose a central role of TLR2 in the
pathophysiology of rosacea (Yamasaki and Gallo, 2009). In
fact, the authors demonstrate that lesional skin of rosacea
patients is characterized by an altered TLR2 expression,
which enhances the susceptibility toward innate immune
stimuli (Schauber et al., 2007; Yamasaki et al., 2011). In
rosacea, activation of TLR2 leads to the expression of
abnormally high levels of the antimicrobial peptide cathe-
licidin, which has been shown to promote leukocyte
Table 1. Chemokine receptor repertoire of human
leukocyte subsets
Cell type
Chemokine
receptor Chemokine ligand
TH1 cells CCR5 CCL3, 4, 5, 8, 14, 16
CXCR3 CXCL4, 9, 10, 11
TH2 cells CCR3 CCL5, 7, 8, 11, 13, 15, 16,
24, 26, 28
CCR4 CCL17, 22
CCR8 CCL1
TH17 cells CCR6 CCL20
Monocytes, macrophages,
dendritic cells
CCR1 CCL3, 5, 7, 13, 14, 15, 16,
23
CCR2 CCL2, 7, 8, 13, 16
CCR5 CCL3, 4, 5, 8, 14, 16
CCR6 CCL20
CCR7 CCL19, 21
CXCR4 CXCL12
CX3CR1 CX3CL1
Neutrophils CXCR2 CXCR1, 2, 3, 5, 6, 7, 8
Mast cells CCR1 CCL3, 5, 7, 8, 13, 14, 15,
16, 23
CCR3 CCL5, 7, 8, 11, 13, 15, 16,
24, 26, 28
CCR4 CCL17, 22
CCR5 CCL3, 4, 5, 8, 14, 16
CXCR1 CXCL6, 7, 8
CXCR2 CXCL1, 2, 3, 4, 5, 6, 7, 8
CXCR3 CXCL4, 9, 10, 11
CXCR4 CXCL12
CX3CR1 CX3CL1
Abbreviation: TH, T helper.
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trafficking through the induction of CXCL8 and induce
angiogenesis (De et al., 2000; Koczulla et al., 2003;
Yamasaki et al., 2007). In particular, the induction of CXCL8
by the cationic cathelicidin peptide LL-37 in keratinocytes is
regarded as a crucial event for the recruitment of neutrophils
and hence the formation of pustules (Zhang et al., 2011).
Moreover, a recent study on the role of Propionibacterium
acnes (P. acnes) in acne vulgaris demonstrates the TLR2-
dependent induction of NF-kB, IL-6, CXCL8, and IL-12 (Kim,
2005). These data correlate with analyses in steroid-induced
acneiform eruptions or rosacea-like dermatitis (Shibata et al.,
2009). In fact, Kis et al. (2006) demonstrated for the first time
that the synthetic glucocorticosteroid budenoside enhances
TLR2 in human primary keratinocytes; subsequently, Shibata
et al. (2009) confirmed these findings by showing that
dexamethasone and cortisol in combination with IL-1a and
TNF-a synergistically increase the expression of TLR2 in
keratinocytes. Subsequently, microbial products derived from
P. acnes activate TLR2 signaling, leading to the induction of
proinflammatory effectors, such as cytokines and chemo-
kines, and hence, mediating skin inflammation as previously
described. Taking into account the high prevalence of
D. folliculorum in rosacea, similar mechanisms may be
proposed for this saprophyte and its associated so-called
mite-related bacteria, e.g., Bacillus olenorium, in rosacea
(Lacey et al., 2007; Hsu et al., 2009; Lazaridou et al., 2011).
Correspondingly, a recent study on the concentration of
inflammatory cytokines and chemokines in the tear fluids of
patients with Demodex blepharitis demonstrated an increase
of IL-7, IL-12, and IL-17 as compared with Demodex-free
blepharitis (Kim et al., 2011). Interestingly, IL-1 and the TLR2-
induced IL-6 (as well as IL-23) promote the TH17 differentia-
tion of human T cells, with TH17 cells representing an
abundant source of IL-17, IL-21, and IL-22 (Chen and O’Shea,
2008). Moreover, a recent study reports an increase of TH17
cells and elevated levels of the TH17 cytokine IL-22 in
peripheral blood of patients with acute generalized exanthe-
matous pustulosis. Acute generalized exanthematous pustu-
losis is an inflammatory dermatosis that is characterized by a
massive subcorneal infiltration of neutrophils. In these cases,
the IL-17/IL-22-mediated induction of CXCL8 in keratinocytes
is the proposed mechanism for the recruitment of neutrophil
granulocytes to the skin, and hence for the formation of
pustules (Kabashima et al., 2011). In summary, these findings
may point toward a potential role for IL-17 and IL-10 family
members in the initiation of pustular lesions seen in rosacea
patients.
With regard to IL-1a, it has been proposed to have a
crucial role in the pathophysiology of ocular rosacea by
inducing a set of MMPs that subsequently degrade extra-
cellular matrix components of the eyelid and the ocular
surface (Matsubara et al., 1991a; Barton et al., 1997; Afonso
et al., 1999; Rao et al., 2008). Specifically, the expression of
MMP9 strongly correlated with the level of IL-1a in the tear
fluid of rosacea patients (Afonso et al., 1999). MMP9 is
produced by the corneal epithelium and has been shown to
be overexpressed in nonhealing corneal ulcers and to
critically participate in the degradation of the corneal
epithelial basement membrane (Matsubara et al., 1991b; Ye
and Azar, 1998). Nevertheless, a study by Robinson et al.
(2003) reports different results for the expression of IL-1a in
the skin of rosacea patients. The authors detected decreased
levels of IL-1a in lesional and non-lesional skin of rosacea
patients (n¼ 11) as compared with the skin of normal
subjects (n¼22). However, they observed significantly
increased levels of the IL-1a-inhibiting IL-1RA and elevated
IL-1RA/IL-1a ratios. Notably, the authors themselves discuss
these somewhat surprising results and argue that increased
levels of IL-1a may qualify as an indicator of acute
inflammation, whereas chronic inflammation may result in
decreased IL-1a levels and reactive induction of IL-1RA
(Robinson et al., 2003). Further research is required to solve
the involvement of IL-1 family members in different stages of
rosacea.
UV RADIATION AND ROS
Rosacea is considered to be a UV-aggravated disease
(Murphy, 2004; Buechner, 2005; Fimmel et al., 2008;
Yamasaki and Gallo, 2009). This concept is supported by
the histopathological observation that all subtypes and
variants of rosacea start as actinic lymphatic vasculopathy
(Fimmel et al., 2008). This condition is accompanied by a
distinct perivascular lymphocytic infiltrate (Fimmel et al.,
2008). Notably, UV irradiation induces IL-1b, IL-6, IL-10,
TNF-a, and CXCL8 in a time- and dose-dependent manner
(Brink et al., 2000; Caricchio et al., 2003; Pauloin et al.,
2009). In particular, the primary proinflammatory cytokines
IL-1b and TNF-a are known to induce the expression of a
subset of proinflammatory chemokines (CXCL1, CXCL8,
CCL20, CCL27) in keratinocytes. Recently, Meller et al.
(2005) demonstrated that UVB irradiation significantly
enhances the expression of the inflammatory chemokines
CCL5, CCL20, and most notably CXCL8, suggesting a
potential pathway for TH1 (CCL5) and TH17 (CCL20) cells,
as well as neutrophil (CXCL8) recruitment. Moreover, UV
radiation is the most important source of ROS in the skin.
Elevated levels of ROS have been observed in the skin of
rosacea patients as compared with healthy individuals (Jones,
2004; Bakar et al., 2007). ROS exert significant proinflam-
matory effects in the skin. In fact, TLR2-ROS signaling has
been shown to mediate the expression of CCL2 and CXCL8 in
primary human monocytes (Lee et al., 2009a). Finally,
current concepts on rosacea pathophysiology suggest a
prominent role for the ‘Myleoid Differentiation Factor 88’
(MyD88) as an effector of UV-induced aggravation (Yamasaki
and Gallo, 2009). MyD88 is an essential adaptor molecule
for TLR signaling and is overexpressed in both UV-irradiated
human primary keratinocytes and chronically UV-exposed
and photoaged human skin (Lee et al., 2009b). Herein,
MyD88 regulates the basal and UV-induced expression of
MMP-1 and IL-6 (Lee et al., 2009b). These molecular
observations may provide a clue for the susceptibility of
UV-sensitive ‘celtic’ individuals to develop rosacea. Surpris-
ingly, a recent study by Salamon et al., (2008) reported
significantly decreased levels of IL-6 and IL-18 in the serum
levels of 60 rosacea patients as compared with 25 healthy
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controls, whereas alterations in the concentrations of TNF-a
and c-reactive protein (CRP) were not detected. Nevertheless,
it is debatable whether serum levels of cytokines reflect
inflammatory processes in lesional skin of rosacea patients.
VASCULAR AND PHYMATOUS CHANGES
Rosacea is defined as an actinic vasculopathy (Fimmel et al.,
2008). The concept of an altered vascular function or a
vascular hyperreactivity is supported by the characteristic
clinical features including flushing, persistent erythema, and
teleangiectasia. Functional analyses have demonstrated that
papulopustular rosacea exposed an increased blood flow as
compared with unaffected skin. Moreover, the increased
blood flow showed a high correlation with the skin
temperature (Guzman-Sanchez et al., 2007). Nevertheless,
vascular changes in rosacea are not limited to functional
changes. Recent studies point toward a vascular endothelial
growth factor (VEGF)-mediated angiogenesis and lymphan-
giogenesis in rosacea (Gomaa et al., 2007). Interestingly, IL-
17 mediates the induction of VEGF in fibroblasts in vitro,
pointing toward a potential role of this cytokine in rosacea-
associated angiogenesis (Numasaki et al., 2003; Tartour
et al., 2011). Conversely, the therapeutic effect of retinoids in
rosacea may in part be mediated by an impairment of the
secretion of VEGF by keratinocytes (Lachgar et al., 1999).
Interestingly, increased vascular densities were correlated
with the subtype of papulopustular rosacea and ocular
rosacea (Aroni et al., 2008).
Notably, chemokines have been shown to exert bimodal
functions on the vasculature. Whereas IFN-inducible and
CXCR3-binding chemokines such as CXCL9, CXCL10, and
CXCL11 have been classified as angiostatic chemokines,
CCL2, CCL11, CXCL1, CXCL8, CXCL12, and CX3CL1 have
been demonstrated to promote angiogenesis (Gerber et al.,
2009). Nevertheless, their role in rosacea-associated vasculo-
pathy and angiogenesis or lymphangiogenesis remains to be
elucidated.
A somewhat separate aspect in the context of cytokines
and rosacea is the proposed role of TGF-b signaling in
phymatous rosacea (Payne et al., 2002, 2006). A persistent
overexpression or dysregulated activation of this cytokine is
suggested to promote fibrosis in phymatous tissue. In fact, the
fibrogenic TGF-b isoforms TGF-b1 and TGF-b2, along with
the TGF-b type II receptor, have been shown to be
overexpressed in rhinophyma (Pu et al., 2000; Payne et al.,
2002, 2006).
NEUROGENIC INFLAMMATION
The concept of cutaneous neurobiology includes a complex
system of closely related mono- and/or bidirectional
pathways that link the skin with the endocrine, the immune,
and the nervous system. These regulate a variety of
physiological and pathophysiological functions including
cellular development, growth, differentiation, vasoregulation,
pruritus, wound healing, and most importantly immunologi-
cal processes and leukocyte recruitment or neurogenic
inflammation. Mediators involved in these processes are
defined as neuropeptides, neurotransmitters, neurotrophins,
and neurohormones, which target various skin cells including
keratinocytes, mast cells, Langerhans cells, microvascular
endothelial cells, fibroblasts, and infiltrating immune cells
(Steinhoff et al., 2003). The release of these mediators is
induced by a broad range of stressors and stimuli, including
rosacea trigger factors such as UV radiation, heat, cold,
microbial agents, or chemicals (including spicy food). The
neuropeptide that has been shown to be dysregulated in
rosacea is substance P (Powell et al., 1993; Fimmel et al.,
2008; Kulka et al., 2008). Substance P induces the production
of TNF-a, IL-3, CCL2, CXCL9, CXCL10, CCL5, and CXCL8 in
human mast cells (Kulka et al., 2008). Hence, neuropeptide-
induced mast cell activation in rosacea might support
dendritic cell/macrophage precursor recruitment via CCL2,
enhance TH1 lymphocyte infiltration through CCL5, CXCL9,
or CXCL10, and finally facilitate perifollicular neutrophil
infiltration and pustule formation through the release of
CXCL8.
INHIBITION OF EGFR-SIGNALING
In recent years, pharmacological EGFR inhibitors (EGFRI)
have been successfully established in the targeted therapy of
various cancer entities (Ciardiello and Tortora, 2008).
Rosacea-like papulopustular eruptions (rash) are the most
frequent adverse effects of EGFRI and occur in 490% of the
treated patients (Lacouture, 2006; Gerber et al., 2010b).
Besides inflammatory papules and pustules, the rash is also
characterized by additional features and characteristics of
rosacea such as teleangiectasia, stinging, and burning, the
presence of large numbers of dermal mast cells, a high
density of D. folliculorum, or an aggravation by UV exposure,
as well as therapeutic responses to systemic tetracyclines
(TCN) or topical calcineurin inhibitors (Gerber et al.,
2010a, b, 2011a, b). Therefore, the EGFRI-associated rash is
a probable pharmacological model of rosacea. In accordance
with rosacea, cytokines and chemokines have a crucial role
in the pathophysiology of EGFRI rashes. EGFRI induce the
expression of cytokines such as IL-6 and IL-7, along with a set
of chemokines, including CCL2, CCL3, CCL5, CCL18, XCL1,
CXCL9, CXCL10, and CX3CL1 (Mascia et al., 2003; Pastore
et al., 2005; Lacouture, 2006).
REGULATION BY ANTI-ROSACEA DRUGS
TCN derivates such as doxycycline are well established in the
treatment of papulopustular dermatoses such as acne vulgaris
or rosacea for decades (Sneddon, 1966; Korting and
Schollmann, 2009b). Herein, not the antibiotic but rather
the immunomodulatory properties of TCN are regarded
responsible for the therapeutic effects (Del Rosso, 2007).
Notably, doxycycline in subantimicrobial doses (40mg once
daily) has been approved in the United States for the long-
term treatment of rosacea for up to 12 months (Baldwin,
2007). The immunomodulatory effects of TCN are caused by
the regulation of cytokines and chemokines to a large extent.
A study by Shapira et al. (1996) demonstrates that TCN
derivatives significantly impair the secretion of IL-1b and
TNF-a in human monocytes. Recently, Bender et al. (2008)
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could demonstrate that TCN derivatives dose dependently
inhibit the release of CXCL8 and CXCL1, and to a smaller
extent CCL2, in primary human dermal microvascular
endothelial cells in vitro. Down this line, Eklund and Sorsa
(1999) showed that TCN derivatives inhibited the production
of CXCL8 in mast cells. Finally, TCN derivatives have been
shown to affect the expression of IL-10 (Chung et al., 2008).
Besides their direct effects on chemokines and cytokines,
antibiotics modulate the effects of a variety of rosacea trigger
factors, thereby indirectly affecting the expression of cyto-
kines and chemokines. In this line, TCN and metronidazole
have been shown to impair the generation of ROS in
neutrophilic granulocytes (Miyachi et al., 1986; Akamatsu
et al., 1990; Sapadin and Fleischmajer, 2006; Golub et al.,
2008). Additional antibiotics that are applied in the manage-
ment of rosacea and those that expose antioxidative proper-
ties include erythromycin and azithromycin (Jain et al., 2002;
Bakar et al., 2007). Finally, metronidazole, which is regarded
as a standard therapy for rosacea, has been shown to
effectively reduce the density of D. folliculorum, thereby
likely impairing a potential induction of NF-kB, IL-6, IL-7,
CXCL8, IL-12, and IL-17 via TLR2 activation by conserved
products derived from D. folliculorum (Kocak et al., 2002;
Schaller et al., 2003).
CONCLUSION
Clearly, our current understanding of the involvement of
cytokines and chemokines is insufficient and further systema-
tic research is required. Nevertheless, a model for the
cytokine and chemokine network of rosacea may be
postulated by extrapolating from known clinical trigger
factors and current pathophysiological concepts: external
and internal trigger factors induce primary proinflammatory
cytokines such as TNF-a and IL-1 family members through
TLR2 signaling or other mechanisms (Figure 1). Subsequently,
a first wave of chemokines is produced that leads to the
recruitment of T cells into the perifollicular space. Given the
histopathology of rosacea lesions that show an early
recruitment of lymphocytes followed by neutrophil infiltra-
tion, it is conceivable that TH1 or TH17 cells are initially
recruited. In turn, T cell-derived cytokines such as IL-17 or IL-
22 may, together with UV radiation, activate keratinocytes to
produce CXCL1 and CXCL8 and facilitate neutrophil recruit-
ment. Interestingly, TH17 cells preferentially express the
chemokine receptor CCR6, and its specific ligand CCL20 is
upregulated by UVB irradiation or TNF-a/IL-1 stimulation in
keratinocytes. Simultaneously, IL-17 promotes angiogenesis
via the induction of VEGF. Besides VEGF, the formation of the
vascular phenotype observed on rosacea is likely to be
supported by the chronic effect of other angiogenic mediators
such as CCL2, CXCL1, or CXCL8. An interesting aspect for
further research is the involvement of cytokines and
chemokines in changes of the lymphatic vessel system seen
in rosacea.
Taking into account the crucial role of cytokines and
chemokines in a broad variety of physiological and patho-
logical processes, the systematic analysis of the cytokine and
chemokine network in rosacea is a promising step toward a
better understanding of this disease, as well as the develop-
ment of novel, mechanism-based therapies.
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